Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study

Abstract

Background Patients with transfusion-dependent thalassemia (TDT) require lifelong blood transfusions and iron chelation therapy. Thus, patients afflicted with TDT often have to undergo blood transfusion and iron chelation therapy, which causes a major economic burden on them. However, this topic has not been reported in Dubai, United Arab Emirates (UAE). Hence, this study aimed to evaluate healthcare resource utilization and associated direct costs related to patients with TDT in Dubai, UAE. Methods For this study, a retrospective prevalence-based cost-of-illness analysis based on the UAE healthcare system and patient perspectives was conducted among patients with TDT treated at the Dubai Thalassemia Center in 2019. Information regarding healthcare resource utilization and direct medical costs was collected from the billing system connected to the electronic medical record system. Patients and their families were interviewed for direct non-medical cost estimations. Results A total of 255 patients with TDT were included in the study. The mean annual direct medical cost was estimated at AED 131,156 (USD 35,713) (95% CI: 124,735 – 137,578). The main driver of the medical cost for the participants as iron chelation therapy AED 78,372 (95% CI: 72,671 – 84,074) (59.8%), followed by blood transfusions, which accounted for AED 34,223 (95% CI: 32,854 – 35,593) 26.1% of the total direct medical costs. The mean annual direct non-medical costs was AED 2,223 (USD 605) (95% CI: 1,946 – 2,500). Age (p < 0.001), severe serum ferritin levels (p = 0.016), the presence of complications (p < 0.001), and the type of iron chelation therapy (p < 0.001) were significant predictors of higher direct medical costs incurred by the participants. Conclusion Transfusion-dependent thalassemia poses a substantial economic burden on the healthcare system, patients, and their families. Our results show that the highest medical cost proportion was due to iron chelation therapy. In this regard, efforts must be made to improve the patients’ acceptance and satisfaction with their iron chelation therapy to increase their compliance and improve the effectiveness of treatment, which could play an essential role in controlling the economic burden of this disease. Moreover, greater support is essential for families that suffer catastrophic out-of-pocket expenses.

Thalassemia care in Nepal: In dire need of improvement

“…In contrast, the prevalence of thalassemia is widespread across the nation and all ethnic groups [ 4 ]. Thalassemia is associated with significant consumption of healthcare resources [ 5 ]. In Nepal, the financial burdens associated with thalassemia diagnosis and treatment have not been studied.…”

The use of generic medications in thalassemia and hemoglobinopathies: challenges, benefits, and economic impact

“…The main driver of the medical costs for the participants is iron chelation therapy, which accounts for AED 78,372 (59.8%) of the total direct medical costs. 5 However, it is important to note that the financial cost of thalassemia may vary depending on the healthcare system, country, and individual patient factors. The considerable economic burden poses challenges for ensuring sustained access to optimal therapy for patients in Europe.…”

Differences in medical costs between TCM users and TCM nonusers in inpatients with thalassemia

“…Thalassemias are a group of inherited hematologic disorders caused by defects in the synthesis of one or more of the hemoglobin chains [ 1 ], α thalassemia and β thalassemia are most common clinically. There were about 399 million thalassemia carriers in 2019 worldwide [ 2 ], mainly in sub-Saharan Africa, the Mediterranean region, and East and South-East Asia, and thalassemia is becoming more common in Europe and North America due to migration factors [ 3 , 4 ]. The increased morbidity of thalassemia has resulted in serious health threats and heavy economic burdens to the patients [ 5 ], especially in low and middle-income countries [ 4 ].…”

“…The increased morbidity of thalassemia has resulted in serious health threats and heavy economic burdens to the patients [ 5 ], especially in low and middle-income countries [ 4 ]. It was estimated that the global cost of treatment for thalassemia was approximately USD842 million in 2017 and is expected to increase by 7.9% from 2018 to 2026 [ 2 ]. In the 2017 Global Burden of Disease report, thalassemia has resulted in 582,000 disability-adjusted life-years (DALYs) [ 6 ].…”